LumiraDx Limited Warrant
LMDXW
LMDXW was delisted on the 8th of January, 2024.
2 hedge funds and large institutions have $72.8K invested in LumiraDx Limited Warrant in 2024 Q2 according to their latest regulatory filings, with funds opening new positions, increasing their positions, reducing their positions, and 2 closing their positions.
70% more capital invested
Capital invested by funds: $42.9K → $72.8K (+$29.9K)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
50% less funds holding
Funds holding: 4 → 2 (-2)
100% less first-time investments, than exits
New positions opened: 0 | Existing positions closed: 2
Top Buyers
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Goldman Sachs
New York
|
-$2.16K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
CH
1
CVS Health
Woonsocket,
Rhode Island
| $72.8K | – | – | – |
|
|
AA
2
Ancora Advisors
Cleveland,
Ohio
| $9 | – | – | – |
|
|
3
Goldman Sachs
New York
| – | -$2.16K | -215,680 | Closed |
|
LMDXW Hedge Fund Activity: Q2 2024 in Review
2 of the 6,925 institutional investors tracked by Wall St. Rank reported a position in LumiraDx Limited Warrant (LMDXW) for Q2 2024, worth a combined $72.8K — up 70% from $42.9K a quarter earlier.
Sellers outnumbered buyers: 2 funds closed out of LMDXW and 0 opened new positions — a net loss of 2 holders — while 0 trimmed existing stakes and 0 added.
The largest seller was Goldman Sachs, exiting entirely with an estimated $2.16K sold.
- 2 institutional investors held LumiraDx Limited Warrant (LMDXW) as of Q2 2024, down from 4 in Q1 2024.
- Funds reported $72.8K of LumiraDx Limited Warrant stock for Q2 2024, up 70% quarter-over-quarter.
- 0 funds opened new LumiraDx Limited Warrant positions in Q2 2024 and 2 closed out, a net change of -2 holders.
- The largest LumiraDx Limited Warrant seller in Q2 2024 was Goldman Sachs, an estimated $2.16K sold.
Based on aggregated 13F filings for Q2 2024.